Darrin Disley
Director/Miembro de la Junta en ROQUEFORT THERAPEUTICS PLC .
Fortuna: 82 409 $ al 30/04/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Martin Evans | M | 83 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Oncogeni Ltd.
Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 años |
Ajan Reginald | M | 52 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | 15 años |
David Preston | M | 57 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Julian Gough | M | 50 |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | 15 años |
Jose Polo | M | - |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | 15 años |
Owen Rackham | M | - |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | 15 años |
Trevor Ajan Reginald | M | 52 |
Oncogeni Ltd.
Oncogeni Ltd. BiotechnologyHealth Technology Part of Roquefort Therapeutics Plc, Oncogeni Ltd. operates as a British biotechnology company. The company is based in Stratford-upon-Avon, UK. The company was founded in 2019 by Nobel Laureate, Martin John Evans, Trevor Ajan Reginald. Oncogeni was acquired by Roquefort Therapeutics Plc on September 16, 2022 for $4.61 million. | 5 años |
Stephen Paul West | M | 51 | 4 años | |
Lorenz Mayr | M | - |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Sabena Sultan | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Graham Robertson | M | - | - | |
Giulio Cossu | M | - |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | - |
Simon Sinclair | M | 52 | 2 años | |
Nigel James Scott | M | 73 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Duncan Mark Powell Ribbons | M | 46 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Jean Duvall | F | 63 | 2 años | |
Lee Phillip Chapman | M | 48 |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Fiona Murray | M | - |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Jane Osbourn | M | - |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | 5 años |
Armand Keating | M | - | 2 años | |
Harry Hoelzer | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Thomas Graney | M | 60 |
Mogrify Ltd.
Mogrify Ltd. BiotechnologyHealth Technology Mogrify Ltd. engages in the development of direct cellular conversion technology. It applies its technology to generate internet protocol and cell types that will power the development and manufacture of new cell therapies in any therapeutic area. The company was founded by Julian Gough, Owen John Llewellyn Rackham, and Jose Polo in 2009 and is headquartered in Cambridge, the United Kingdom. | 3 años |
Stephen Westaby | M | - |
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | - |
Gary Pisano | M | 62 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Chaim Hurvitz | M | 63 |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Conor Kehoe | M | - |
Celixir Plc
Celixir Plc Pharmaceuticals: MajorHealth Technology Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Mark Freeman | M | 49 | 1 años | |
Michael Stein | M | 60 | 3 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Reino Unido | 28 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Darrin Disley
- Red Personal